4R6S

Crystal structure of PPARgammma in complex with SR1663

4R6S の概要

• エントリーDOI: 10.2210/pdb4r6s/pdb
• 関連するPDBエントリー: 4R2U
• 分子名称: Peroxisome proliferator-activated receptor gamma, 4'-[(2,3-dimethyl-5-{[(1R)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid (3 entities in total)
• 機能のキーワード: nuclear receptor ligand binding domain, transcription
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Nucleus: P37231
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 64086.38

構造登録者

Marciano, D.P.,Griffin, P.R.,Bruning, J.B. (登録日: 2014-08-26, 公開日: 2015-07-01, 最終更新日: 2023-09-20)

主引用文献

Marciano, D.P.,Kuruvilla, D.S.,Boregowda, S.V.,Asteian, A.,Hughes, T.S.,Garcia-Ordonez, R.,Corzo, C.A.,Khan, T.M.,Novick, S.J.,Park, H.,Kojetin, D.J.,Phinney, D.G.,Bruning, J.B.,Kamenecka, T.M.,Griffin, P.R.
Pharmacological repression of PPAR gamma promotes osteogenesis.
Nat Commun, 6:7443-7443, 2015

PubMed Abstract: The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of insulin sensitizers. Activation of PPARγ by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing to their associated adverse effects on bone. Recently, we reported the development of PPARγ antagonist SR1664, designed to block the obesity-induced phosphorylation of serine 273 (S273) in the absence of classical agonism, to derive insulin-sensitizing efficacy with improved therapeutic index. Here we identify the structural mechanism by which SR1664 actively antagonizes PPARγ, and extend these findings to develop the inverse agonist SR2595. Treatment of isolated bone marrow-derived mesenchymal stem cells with SR2595 promotes induction of osteogenic differentiation. Together these results identify the structural determinants of ligand-mediated PPARγ repression, and suggest a therapeutic approach to promote bone formation.

PubMed: 26068133
DOI: 10.1038/ncomms8443

実験手法

X-RAY DIFFRACTION (2.301 Å)